Patient must have a histologically proven adenocarcinoma of colon or rectum cancer.
Patients must have a performance status of 0,1, or 2 by the Southwest Oncology Group criteria.
Patients must have recovered from any effects of surgery.
Evaluable disease must be present outside radiation field. At least 3 weeks must have elapsed after discontinuation of radiation therapy.
Patients must provide a signed consent to participate in the study.
Patients must complete all questionnaires.
You may not be if
Patients with a proven history of peptic ulcer disease or gastroesophageal reflux.
History of other malignancy, except for cancers that have been treated with a curative intent and patient is without evidence of active disease.
Unresolved bacterial infection requiring treatment with antibiotics.
Pregnant or lactating women may not participate in the study.
Patients known to have HIV-1 virus infection because of the undetermined effect of this chemotherapy regimen in patients with HIV-1 and the potential for serious interaction with anti-HIV medications.
Gilbert's disease.
Other serious concurrent infection
Clinically significant cardiac disease not well controlled with medication (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias) or myocardial infarction within the last 12 months.
